10-10-2019 дата публикации
Номер: WO2019192403A1
Принадлежит:
Disclosed in the present invention are an LGR4/RSPO blocker and an anti-immune checkpoint inhibitor jointly used for tumor immunotherapy, specifically disclosing a product combination, comprising: (i) a first pharmaceutical composition, the first pharmaceutical composition comprising (a) a first active ingredient, the first active ingredient being an LGR4/RSPO blocker, as well as a pharmaceutically acceptable carrier; and (ii) a second pharmaceutical composition, the second pharmaceutical composition comprising (b) a second active ingredient, the second active ingredient being an inhibitor of an anti-immune checkpoint, and the immune checkpoint being selected from the following group: PD-1, PD-L1, CTLA-4, TIM3, TIGIT\ICOS, LAG3, OX40, CD47, VISTA, and 4-1BB or a combination thereof; and a pharmaceutically acceptable carrier. The present invention combines an LGR4/RSPO blocker and an anti-immune checkpoint inhibitor, and may be effectively used for (i) treating tumors; (ii) inhibiting tumor ...
Подробнее